# Solubility enhancement via amorphous solid dispersions: Extended functionality by applying a versatile polyvinyl alcohol platform for hot melt extrusion

Nicole Di Gallo<sup>\*</sup>, Alessandro Giuseppe Elia<sup>\*</sup>, Nabil Lamrabet<sup>\*</sup>, Thomas Kipping<sup>\*</sup>

## Purpose

The limited number of available polymers for hot melt extrusion is a challenge for formulators. Often the development focus is laid only on ASD stability. Novel ASD formulations are also targeting an enhanced functionality by the integration of additional polymers or surfactants.<sup>1</sup>

# **Objectives**

Development of a broad polymer platform, based on polyvinyl alcohol (PVA).

Understand the impact of molecular design of PVA on the performance of the polymer for the creation of amorphous solid dispersions.

# Methods

#### Melt Rheology

Thermo-Fisher Scientific Haake Mars Rheo 60 (Thermo Fisher Scientific, Waltham, USA) temperature ramp from 170 °C to 230 °C (3-82)/250 °C (4-88)  $\Delta T/t=2$  °/min oscillating Controlled Deformation, CD,  $y_0=0.1\%$ , f=1.0 Hz Gap=1 mm, plate-plate geometry 25 mm diameter

#### Dissolution

pH-shift method (750 mL 0.1M HCl for 120 Min, add 250 mL PP pH 6.8 final 1,000 mL) HME formulation 20% drug load; Paddle; 50 rpm; total runtime 300 Min, n=3 via HPLC measurement.

### **Hot Melt Extrusion**

Pharma 11 (Thermo Fisher Scientific, Waltham, USA) Die: 2 mm; Screw configuration containing three kneading elements Gravimetric feeding: Congrav OP1-S, downstream, via conveyor belt (Brabender GmbH, Duisburg, Germany)

### **Differential Scanning Calorimetry**

DSC 3+ (Mettler Toledo, USA) sample mass  $\approx$  5 mg, n=3, 40µl Al-pan 1. 1st heating cycle -20 °C to 210 °C 2. isothermal at 210,0 °C, 3,00 min, 3. cooling cycle 210 °C to -20 °C,

4. isothermal at -20,0 °C, 3,00 min,

5. 2nd heating cycle -20 °C to 250°C

50 ml/min N2, heating/cooling rate 5 K/min, data evaluated with STARe-Excellence Software

# Results



Figure 1.

Simplified schematic view of the Hot Melt Extrusion (HME) process, visualizing the transition of API and matrix polymer from feeder to the extruder die.

The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.

© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the Vibrant M, SAFC and Parteck are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MK\_PS12782EN 10/2023

DISPERSION



Chemical structure of a partially hydrolyzed PVA.

PVA 3-82 and 4-88 are thermostable polymer designed for HME. • The first number specifies the apparent viscosity in mPas of a 4% aqueous solution at 20 °C which is also linked to the relative

molecular weight of the polymer chain. • The second number represents the degree of hydrolysis of the



Figure 3 DSC profiles of MXP 3-82 and MXP 4-88. A higher hydrolysis grades show a shift of thermal events to higher temperatures which correlates with rheological behavior.



Figure 4. processing range.

Melt rheology of both PVA 3-82 and 4-88 showed a significant difference in crossover points as well as the expectable process window. While the viscosity of PVA 4-88 remains quite high until a temperature of ~200 °C and G' (storage modulus) remains the dominant modulus, a crossover of G' and G''(Loss modulus) can be observed at 203 °C within a significant drop in melt viscosity. A second crossover of G'' and G' along with a decreasing phase angle  $\delta$  indicates the begin of polymer degradation at around 235 °C. In contrast, MXP 3-82 G'' is already the prominent modulus over G' at 170 °C, along with a constant decrease of melt viscosity when increasing the melt temperature. At around 212 °C a G''/G'crossover as well the drop of phase angle  $\delta$  indicates a beginning degradation of the polymer melt. The observed rheological behavior of both polymers indicated that extrusion range in terms of barrel temperature as well as torque is lower for 3-82 then for 4-88. Several conducted HME trials both with 3-82 and 4-88 proved that the process range of 3-82 is feasible at 130–210 °C\* and 150–230 °C\* for 4-88, which correlates to the rheological data generated (see Fig. 4). \*incl. addition of plasticizer

Parteck <sup>®</sup> MXP 3-82		
Media	рН	Solubility at 37 °C (mg/mL)
SGF_sp	2	272.8
0.1M HCI	1	67.9
Acetate buffer	4.5	67.1
FaSSIF	6.5	60.9
PBS	6.8	57.45
PBS	7.4	215
Parteck® MXP 4-88		
THREEK MAR + 00		
Media	рН	Solubility at 37 °C (mg/mL)
Media SGF_sp	<b>рН</b> 2	Solubility at 37 °C (mg/mL) 199.2
Media SGF_sp 0.1M HCI	<b>рН</b> 2 1	Solubility at 37 °C (mg/mL)       199.2       51.55
Media SGF_sp 0.1M HCI Acetate buffer	рН 2 1 4.5	Solubility at 37 °C (mg/mL)       199.2       51.55       257.6
Media   SGF_sp   0.1M HCI   Acetate buffer   FaSSIF	pH 2 1 4.5 6.5	Solubility at 37 °C (mg/mL)     199.2     51.55     257.6     55.25
Media SGF_sp 0.1M HCI Acetate buffer FaSSIF PBS	pH 2 1 4.5 6.5 6.8	Solubility at 37 °C (mg/mL)       199.2       51.55       257.6       55.25       54.8

Table 1. Solubilities of both 3-82 and 4-88 in different dissolution media.



Figure 6.

The dissolution data shows for a low hydrolysis grade outstanding supersaturation performance after shifting the pH from gastric to intestinal fluid conditions which is useful for hydrophobic API's like itraconazole as model compound.



For PVA based polymers the hydrolysis degree is impacting the process temperature range and thermal behavior (Fig. 3 & 4). The chance in amphiphilic structure is also affecting the solubility in relevant media (see Table 1). Higher hydrolyzed PVAs show a superior temperature tolerance, whereas low hydrolyzed PVA can be utilized at lower process temperature and prove to be very effective in prolongating the supersaturated state of low soluble drug substances (Fig. 6).

#### References

- \* Merck KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany.

Melt viscosity data for Parteck<sup>®</sup> MXP 3-82 and Parteck<sup>®</sup> MXP 4-88 indicating a broad

#### Contact details: thomas.kipping@milliporesigma.com

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.



Dissolution data of drug loaded extruded matrices; assessment via pH shift.

1. Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharmaceutica Sinica B. 2021;11(8):2505-36.

